Moderna (MRNA) reported second-quarter 2026 revenue of $145 million, up from $142 million in the same period in 2025. The company posted a GAAP net loss of $782 million, compared with a net loss of $825 million a year earlier, and GAAP loss per share of $1.97.
Moderna reiterated its plan to deliver up to 10% revenue growth in 2026 and improved its 2026 GAAP operating expense outlook by about $0.2 billion. The company also said it anticipates a potential U.S. approval decision for mFLUSIVA on August 5 and is preparing to enroll an additional cohort in its norovirus vaccine trial after an interim analysis did not meet statistical criteria for early success.
- Second-quarter revenue was $145 million, including $87 million in the U.S. and $58 million in international markets.
- Cost of sales was $93 million, down 22% from the year-earlier period.
- Research and development expenses were $651 million, down 7% year over year.
- Selling, general and administrative expenses were $216 million, down 6% year over year.
- Cash, cash equivalents and investments were $6.9 billion as of June 30, 2026.
- Year-end 2026 cash and investments are projected at $4.7 billion to $5.2 billion.
$MRNA Insider Trading Activity
$MRNA insiders have traded $MRNA stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) has made 0 purchases and 4 sales selling 320,017 shares for an estimated $16,741,685.
- SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 17,356 shares for an estimated $899,596.
- NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
- ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MRNA Hedge Fund Activity
We have seen 352 institutional investors add shares of $MRNA stock to their portfolio, and 297 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 17,626,713 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $848,197,429
- CAPITAL WORLD INVESTORS added 5,869,654 shares (+45.8%) to their portfolio in Q1 2026, for an estimated $282,447,750
- BLACKROCK, INC. removed 2,869,857 shares (-8.8%) from their portfolio in Q1 2026, for an estimated $138,097,518
- GOLDMAN SACHS GROUP INC added 2,653,078 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $127,666,113
- WELLINGTON MANAGEMENT GROUP LLP added 2,274,302 shares (+2730.4%) to their portfolio in Q1 2026, for an estimated $109,439,412
- TWO SIGMA INVESTMENTS, LP added 1,744,308 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $83,936,100
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,560,559 shares (-96.6%) from their portfolio in Q1 2026, for an estimated $75,094,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
